MPE becomes a member of the Patients’ and Consumers’ Working Party

MPELeave a comment

MPE is very proud to have been accepted as member of the Patients’ and Consumers’ Working Party (PCWP) at the European Medicines Agency for the term 2016-2019. The PCWP provides a platform for exchange of information and discussion of issues of common interest between the EMA and patients and consumers. It was established in 2006, and has enabled the Agency to build upon its existing interactions with patients and consumers. It provides recommendations to the…

CHMP has expressed a negative opinion for ixazomib

Access, MyelomaLeave a comment

Ixazomib (Ninlaro) has received a negative recommendation from the Committee for Human Medicinal Products (CHMP) within the European Medicines Agency. The CHMP is responsible for developing recommendations for the European Commission on new medicines going through the European marketing authorisation process. It assesses and makes recommendations on whether a drug is safe and effective enough to be granted a marketing authorisation for use across the European Union. Usually the European Commission follows the advice of…

Statement from MPE on the court case it has taken against its former treasurer Ms Begoña Barragán

MPELeave a comment

STATEMENT FROM MYELOMA PATIENTS EUROPE on the court case it has taken against its former treasurer Ms Begoña Barragán Brussels, Belgium – Friday May 20th 2016 Myeloma Patients Europe (MPE) believes it has been defrauded by its former Treasurer Ms Begoña Barragán who, between 2013 and 2014, carried out four unauthorised transfers of money from MPE’s bank account to the Spanish organisations AEAL and Fundaseth, which were under her control and responsibility. In total Ms…

What is Minual Residual Disease (MRD) and how it can be monitored?

MPE, MyelomaLeave a comment

New trends in Multiple Myeloma management is to look for the few amounts of cancer cells that might remain in your bone marrow. These residual cells are responsible of the disease relapse. Myeloma Patients Europe will hold an online webinar on Minimal Residual Disease (MRD) that will highlight the importance of this monitoring method and will detail new highly sensitive techniques used to investigate it.

EMA recommends market authorisation for elotuzumab

Access, MyelomaLeave a comment

Elotuzumab receives a positive Committee for Medicinal Products for Human Use (CHMP) opinion for the treatment of multiple myeloma patients who have receive at least one prior therapy. The reccommensation is based in the results of a randomised open-label Phase 3 study evaluating the use of elotuzumab in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethashone alone. The results show that myeloma progresses more slowly on those patients who took elotuzumab compared to those…